{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive+Malignant+Neoplasm+of+Breast",
    "query": {
      "condition": "Hormone Receptor Positive Malignant Neoplasm of Breast"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 65,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive+Malignant+Neoplasm+of+Breast&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T19:36:37.851Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04602117",
      "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2 Low",
        "SYD-985",
        "SYD985",
        "Vic-trastuzumab Duocarmazine",
        "Metastatic Cancer",
        "Metastatic Breast Cancer",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic",
        "HER2 Low Breast Cancer",
        "GastroEsophageal Cancer",
        "Gastroesophageal Adenocarcinoma",
        "Endometrium Tumor",
        "Ovarian Cancer",
        "Ovarian Carcinoma",
        "HER2-positive Gastric Cancer",
        "HER2-positive Metastatic Breast Cancer",
        "HER2 Mutation-Related Tumors",
        "HER-2 Protein Overexpression",
        "HER2 Low HR Positive",
        "HR Positive",
        "Hormone Receptor-positive Breast Cancer",
        "Estrogen Receptor Positive Tumor",
        "Progesterone Receptor-positive Breast Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Negative Breast Carcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-07-28",
      "completion_date": "2021-11-17",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-06-10T19:36:37.851Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04602117"
    },
    {
      "nct_id": "NCT00615524",
      "title": "Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-receptor Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "exemestane and pazopanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2008-04",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2018-01-12",
      "last_synced_at": "2026-06-10T19:36:37.851Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00615524"
    },
    {
      "nct_id": "NCT01870505",
      "title": "BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic or Locally-advanced Unresectable Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BYL719",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 52,
      "start_date": "2013-05",
      "completion_date": "2022-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-12-09",
      "last_synced_at": "2026-06-10T19:36:37.851Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01870505"
    },
    {
      "nct_id": "NCT03691493",
      "title": "Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Estrogen Receptor Positive",
        "HER2/Neu Negative",
        "Metastatic Breast Carcinoma",
        "Metastatic Malignant Neoplasm in the Bone",
        "Progesterone Receptor Positive",
        "Prognostic Stage IV Breast Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2019-02-08",
      "completion_date": "2022-10-13",
      "has_results": true,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-06-10T19:36:37.851Z",
      "location_count": 10,
      "location_summary": "Atlanta, Georgia • Augusta, Georgia • Columbus, Georgia + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03691493"
    },
    {
      "nct_id": "NCT05735080",
      "title": "Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Cancer Metastatic",
        "Hormone Receptor Positive Tumor",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
        "Ovarian Cancer",
        "CCNE1 Amplification",
        "Solid Tumor",
        "Advanced Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "INX-315",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyclix Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2023-03-28",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-06-10T19:36:37.851Z",
      "location_count": 15,
      "location_summary": "Orlando, Florida • Atlanta, Georgia • Augusta, Georgia + 10 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05735080"
    },
    {
      "nct_id": "NCT03088527",
      "title": "Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hormone Receptor Positive Malignant Neoplasm of Breast"
      ],
      "interventions": [
        {
          "name": "RAD140",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stemline Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2017-10-23",
      "completion_date": "2020-09-24",
      "has_results": false,
      "last_update_posted_date": "2022-08-18",
      "last_synced_at": "2026-06-10T19:36:37.851Z",
      "location_count": 5,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03088527"
    },
    {
      "nct_id": "NCT03394027",
      "title": "ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Endometrial Cancer",
        "Hormone Receptor Positive, HER2 Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ONC201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-01-17",
      "completion_date": "2021-10-07",
      "has_results": true,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-06-10T19:36:37.851Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03394027"
    },
    {
      "nct_id": "NCT07205822",
      "title": "A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dato-DXd",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-10-30",
      "completion_date": "2028-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-10T19:36:37.851Z",
      "location_count": 6,
      "location_summary": "Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more",
      "locations": [
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07205822"
    },
    {
      "nct_id": "NCT00293540",
      "title": "Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "oophorectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "International Breast Cancer Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 249,
      "start_date": "2006-02",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-07-27",
      "last_synced_at": "2026-06-10T19:36:37.851Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00293540"
    },
    {
      "nct_id": "NCT01633060",
      "title": "A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "BKM120",
          "type": "DRUG"
        },
        {
          "name": "BKM120 matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 432,
      "start_date": "2012-10-03",
      "completion_date": "2017-09-21",
      "has_results": true,
      "last_update_posted_date": "2019-01-30",
      "last_synced_at": "2026-06-10T19:36:37.851Z",
      "location_count": 37,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01633060"
    }
  ]
}